Register for our free email digests:
AMAG Pharmaceuticals Inc.
http://www.amagpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AMAG Pharmaceuticals Inc.
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Norgine Drives Role As Specialty Partner For Europe
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.
Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
GSK Venture Capital Arm Goes Independent With $500m Fund
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Advanced Magnetics, Inc.
- Cord Blood Registry (CBR)
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Lumara Health Inc.
- Perosphere Inc.
- Perosphere Pharmaceuticals
- Ther-Rx Corporation